Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by geos571on Jun 10, 2015 7:41pm
103 Views
Post# 23818140

RE:donot worry. sample distribution continues

RE:donot worry. sample distribution continues
Yesterday, 07:14 PM
Anonymous
Posts: n/a
DefaultRe: so many are just so jealous of us

Quote:
Originally Posted by AnonymousView Post
It's no coincidence that Horizon has turned the corner once they got ahold of U.S. rights for Pennsaid 2%. It has become a company maker. They need to get the world rights for Pennsaid 2% to really push the international sales of this company! The longer Horizon waits, the Pennsaid 2% world wide rights could go to a competitor like Endo based on what we have started for sales in the U.S. Endo already has the Canadian rights because they bought out Palliden. So Horizon really needs to go get it because others will come.
Nuvo is about to complete phase 3 trials in Germany. But, they will have to pay more than the 45 mil for EU rights, if not the Nuvo shareholder will riot !!!
Reply With Quote

LOL found this to be quite amusing ....
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse